Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis

Stock Information for Lyra Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lyra Therapeutics Inc.

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Lyra Therapeutics, Inc. (NASDAQ: LYRA) and Encourages Investors to Contact the Firm
Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Lyra Therapeutics to Participate in Upcoming Investor Conferences
INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into Lyra Therapeutics, Inc.; Urges Lyra Stockholders to Contact Abbott Cooper Regarding Their Legal Rights
Lyra Therapeutics Announces Appointment of Ronan O'Brien as Chief Legal Officer
Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.